- Home
- BMRA vs MYNZ Comparison
BMRA vs MYNZ Comparison
Compare BMRA & MYNZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BMRA
- MYNZ
- Stock Information
- Founded
- BMRA 1971
- MYNZ 2021
- Country
- BMRA United States
- MYNZ Germany
- Employees
- BMRA N/A
- MYNZ N/A
- Industry
- BMRA Biotechnology: In Vitro & In Vivo Diagnostic Substances
- MYNZ Biotechnology: Pharmaceutical Preparations
- Sector
- BMRA Health Care
- MYNZ Health Care
- Exchange
- BMRA Nasdaq
- MYNZ Nasdaq
- Market Cap
- BMRA 7.6M
- MYNZ 7.9M
- IPO Year
- BMRA N/A
- MYNZ 2021
- Fundamental
- Price
- BMRA $3.47
- MYNZ $1.75
- Analyst Decision
- BMRA
- MYNZ Buy
- Analyst Count
- BMRA 0
- MYNZ 2
- Target Price
- BMRA N/A
- MYNZ $14.00
- AVG Volume (30 Days)
- BMRA 2.1M
- MYNZ 170.7K
- Earning Date
- BMRA 10-14-2025
- MYNZ 03-31-2025
- Dividend Yield
- BMRA N/A
- MYNZ N/A
- EPS Growth
- BMRA N/A
- MYNZ N/A
- EPS
- BMRA N/A
- MYNZ N/A
- Revenue
- BMRA $5,678,000.00
- MYNZ $893,991.00
- Revenue This Year
- BMRA N/A
- MYNZ $26.06
- Revenue Next Year
- BMRA N/A
- MYNZ $4.97
- P/E Ratio
- BMRA N/A
- MYNZ N/A
- Revenue Growth
- BMRA 5.01
- MYNZ N/A
- 52 Week Low
- BMRA $2.08
- MYNZ $1.30
- 52 Week High
- BMRA $10.16
- MYNZ $18.40
- Technical
- Relative Strength Index (RSI)
- BMRA 55.33
- MYNZ 52.10
- Support Level
- BMRA $2.80
- MYNZ $1.70
- Resistance Level
- BMRA $3.26
- MYNZ $1.90
- Average True Range (ATR)
- BMRA 0.32
- MYNZ 0.12
- MACD
- BMRA 0.03
- MYNZ 0.03
- Stochastic Oscillator
- BMRA 37.22
- MYNZ 69.39
About BMRA Biomerica Inc.
Biomerica Inc is engaged in the development, manufacturing, and marketing of medical diagnostic products designed for the early detection and monitoring of chronic diseases and medical conditions. The company focuses on products for gastrointestinal diseases, food intolerances, diabetes, and certain esoteric tests. It operates in one segment namely, the design, development, marketing and sales of diagnostic kits. The majority of the company's revenue is earned from the Asia, and also has its presence in Europe, North America, Middle East and South America.
About MYNZ Mainz Biomed N.V.
Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. The company operates in one operating segment, genetic diagnostic testing.